Pharmacokinetic interaction study of combining imatinib with dasatinib in rats by UPLC–MS/MS

References

• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. New Engl J Med 2001;344:1031–7
   PubMed Web of Science ®Google Scholar
• Bedi A, Zehnbauer BA, Barber JP, et al. Inhibition of apoptosis by BCR–ABL in chronic myeloid leukemia. Blood 1994;83:2038–44
   PubMed Web of Science ®Google Scholar
• O'Hare T, Eide CA, Deininger MW. Bcr–Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007;110:2242–9
   PubMed Web of Science ®Google Scholar
• Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640–53
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358–63
   PubMed Web of Science ®Google Scholar
• Peggs K, Mackinnon S. Imatinib mesylate – the new gold standard for treatment of chronic myeloid leukemia. New Engl J Med 2003;348:1048–50
   PubMed Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399–401
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11:4182–90
   PubMed Web of Science ®Google Scholar
• Zheng S, Huang K-E, Pan Y-L, et al. KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance. Gastric Cancer 2014;17:1–7
   PubMed Web of Science ®Google Scholar
• Lindauer M, Hochhaus A. Dasatinib, in small molecules in oncology. Heidelberg, Berlin: Springer; 2014
   Google Scholar
• Gilbert JA. Dasatinib as first-line therapy for CML-CP. Lancet Oncol 2014;15:e7
   PubMed Web of Science ®Google Scholar
• Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006;108:2332–8
   PubMed Web of Science ®Google Scholar
• Obr A, Roselova P, Grebenova D, Kuzelova K. Real-time analysis of imatinib- and dasatinib-induced effects on chronic myelogenous leukemia cell interaction with fibronectin. PLoS One 2014;9:e107367
   PubMed Web of Science ®Google Scholar
• Zhu Y, Pan L, Hong M, et al. The combination therapy of imatinib and dasatinib achieves longterm molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia. J Biomed Res 2014;28
   Google Scholar
• Wang Z, Sun W, Huang CK, et al. Inhibitory effects of curcumin on activity of cytochrome P450 2C9 enzyme in human and 2C11 in rat liver microsomes. Drug Dev Ind Pharm 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Wang L, Wang S, Chen M, et al. Inhibitory effect of ketoconazole and voriconazole on the pharmacokinetics of carvedilol in rats. Drug Dev Ind Pharm 2014:1–6. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Sun W, Wang Z, Chen H, et al. The effect of clopidogrel on pharmacokinetics of ivabradine and its metabolite in rats. Drug Dev Ind Pharm 2014:1–6. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Wang L, Bao SH, Pan PP, et al. Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro. Drug Dev Ind Pharm 2014:1–5. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Lin G, Wang C, Qiu X, et al. Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat. Drug Dev Ind Pharm 2014;40:1616–22
   PubMed Web of Science ®Google Scholar
• Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44:879–94
   PubMed Web of Science ®Google Scholar
• Luo FR, Yang Z, Camuso A, et al. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res 2006;12:7180–6
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wen C, Xiang Z, et al. Determination of CUDC-101 in rat plasma by liquid chromatography mass spectrometry and its application to a pharmacokinetic study. J Pharm Biomed Anal 2014;90:134–8
   PubMed Web of Science ®Google Scholar
• Wen C, Lin C, Cai X, et al. Determination of sec-O-glucosylhamaudol in rat plasma by gradient elution liquid chromatography–mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 2014;944:35–8
   PubMed Web of Science ®Google Scholar
• Ma J, Lin C, Wen C, et al. Determination of bicuculline in rat plasma by liquid chromatography mass spectrometry and its application in a pharmacokinetic study. J Chromatogr B Anal Technol Biomed Life Sci 2014;953–954:143–6
   PubMed Web of Science ®Google Scholar
• Ma J, Ding X, Sun C, et al. Development and validation a liquid chromatography mass spectrometry for determination of solasodine in rat plasma and its application to a pharmacokinetic study. J Chromatogr B Anal Technol Biomed Life Sci 2014;963:24–8
   PubMed Web of Science ®Google Scholar
• Ma J, Cai J, Lin G, et al. Development of LC–MS determination method and back-propagation ANN pharmacokinetic model of corynoxeine in rat. J Chromatogr B Anal Technol Biomed Life Sci 2014;959:10–15
   PubMed Web of Science ®Google Scholar
• Cai J, Lin C, Ma J, et al. Determination of rhynchophylline in rat plasma by liquid chromatography mass spectrometry and its application. J Chromatogr Sci 2014;52:661–5
   PubMed Web of Science ®Google Scholar
• Wang X, Chen M, Wen C, et al. Determination of chidamide in rat plasma by LC–MS and its application to pharmacokinetics study. Biomed Chromatogr 2013;27:1801–6
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang S, Ding T, et al. Evaluation of the effect of apatinib (YN968D1) on cytochrome P450 enzymes with cocktail probe drugs in rats by UPLC–MS/MS. J Chromatogr B Anal Technol Biomed Life Sci 2014;973C:68–75
   PubMed Web of Science ®Google Scholar
• Gershkovich P, Ibrahim F, Sivak O, et al. A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. Drug Dev Ind Pharm 2014;40:338–44
   PubMed Web of Science ®Google Scholar
• Meher JG, Yadav NP, Sahu JJ, Sinha P. Determination of required hydrophilic–lipophilic balance of citronella oil and development of stable cream formulation. Drug Dev Ind Pharm 2013;39:1540–6
   PubMed Web of Science ®Google Scholar
• Graves RA, Ledet G, Nation CA, et al. An ultra-high performance chromatographic method for the determination of artemisinin. Drug Dev Ind Pharm 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Liu Y, Li X, Yang C, et al. UPLC–MS–MS method for simultaneous determination of caffeine, tolbutamide, metoprolol, and dapsone in rat plasma and its application to cytochrome P450 activity study in rats. J Chromatogr Sci 2013;51:26–32
   PubMed Web of Science ®Google Scholar
• Seong SJ, Lim M, Sohn SK, et al. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. Ann Oncol 2013;24:756–60
   PubMed Web of Science ®Google Scholar
• Li X, He Y, Ruiz CH, et al. Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways. Drug Metab Dispos 2009;37:1242–50
   PubMed Web of Science ®Google Scholar
• Johnson FM, Agrawal S, Burris H, et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 2010;116:1582–91
   PubMed Web of Science ®Google Scholar
• Christopher LJ, Cui D, Wu C, et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 2008;36:1357–64
   PubMed Web of Science ®Google Scholar